Fintel on MSN19h
Leerink Partners Upgrades Genmab A (GMAB)Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...
Hosted on MSN13h
Leerink Partners Downgrades 10x Genomics (TXG)Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Century Therapeutics (IPSC – Research Report) yesterday and set a price ...
Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.
Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...
NeuroPace (Nasdaq:NPCE) today announced that it intends to sell common stock in an underwritten public offering worth $65 ...
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
Stock analysts at Leerink Partnrs upped their Q1 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a ...
Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Axsome Therapeutics in a research report issued ...
Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback